What this means
This study will follow people in five groups, including normal aging and Alzheimer's disease. It plans to collect health data, tests, and samples to find risk factors and early signs.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 40–99
- Where
- 2 sites
The science
- Registered title
- China Longitudinal Aging and Cognitive Impairment Study
- Trial ID
- NCT05468905 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Aging, Mild Cognitive Impairment, Alzheimer Disease, Neurodegeneration
- What is tested
- None of intervention
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Ages
- 40 Years to 99 Years
- Dates
- First posted Jul 21, 2022 · updated Jul 21, 2022
Registry summary
This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive impairment (VCI). The goals of this study are as follow: 1.To establish longitudinal cohort study database containing comprehensive epidemiological data, neuropsychological test data, laboratory parameters, image data and biological samples. 2. To determine the risk factors of AD and other dementias. 3. To explore the conversion rates from CN to SCI, MCI or AD and the risk factors as well as biomarkers for the progression from CN to SCI, MCI or AD. 4. To explore and validate blood, CSF, urine, imaging and other biomarkers for the early detection and progression of AD.
Sites (2)
- Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Zhejiang Lishui central Hospital, Lishui, Zhejiang, China